Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Dean F. Bajorin, Ronald de Wit et al.|New England Journal of Medicine|2017Cited by 3.4k
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upYves Fradet, Dean F. Bajorin, Joaquim Bellmunt et al.|Annals of Oncology|2019Cited by 484
Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodesMaha K. Rahim, Matthew H. Spitzer, Kyle B. Jones et al.|Cell|2023Cited by 410
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancerJacob Stultz, Lawrence Fong|Prostate Cancer and Prostatic Diseases|2021Cited by 224
Predictors of responses to immune checkpoint blockade in advanced melanomaNicolas Jacquelot, Laurence Zitvogel, María P. Roberti et al.|Nature Communications|2017Cited by 201